Top ▲

CD19

Click here for help

Immunopharmacology Ligand  Target has curated data in GtoImmuPdb

Target id: 2764

Nomenclature: CD19

Family: CD molecules

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 1 556 16p11.2 CD19 CD19 molecule 4
Mouse 1 547 7 69.01 cM Cd19 CD19 antigen 4
Rat - 547 1q36 Cd19 CD19 molecule
Database Links Click here for help
CATH/Gene3D
ChEMBL Target
Ensembl Gene
Entrez Gene
Human Protein Atlas
KEGG Gene
OMIM
Pharos
RefSeq Nucleotide
RefSeq Protein
UniProtKB
Wikipedia

Download all structure-activity data for this target as a CSV file go icon to follow link

Antibodies
Key to terms and symbols Click column headers to sort
Antibody Sp. Action Value Parameter Reference
inebilizumab Peptide Approved drug Primary target of this compound Hs Binding 9.3 – 10.3 pKd 1
pKd 9.3 – 10.3 (Kd 5x10-10 – 5x10-11 M) [1]
blinatumomab Peptide Approved drug Click here for species-specific activity table Immunopharmacology Ligand Hs Binding 9.0 pKd 2
pKd 9.0 (Kd 1x10-9 M) [2]
Description: Binding of the single-chain Fv portion of blinatumomab to CD19.
tafasitamab Peptide Approved drug Primary target of this compound Immunopharmacology Ligand Hs Binding - - 3
[3]
Immunopharmacology Comments
CD19 is a B cell antigen used as a biomarker for normal and neoplastic B cells, and follicular dendritic cells. Anti-CD19 monoclonal antibodies are being investigated for potential clinical utility in oncology, transplantation and autimmune diseases (e.g. inebilizumab). Blinatumomab is a bispecific CD19/CD3e mAb already approved as a treatment for Philadelphia chromosome-negative precursor B-cell acute lymphoblastic leukemia (B-cell ALL), an uncommon form of ALL.
Cell Type Associations
Immuno Cell Type:  B cells
Cell Ontology Term:   B cell (CL:0000236)
Immuno Process Associations
Immuno Process:  Inflammation
GO Annotations:  Associated to 1 GO processes
GO:0002322 B cell proliferation involved in immune response IDA
Immuno Process:  Immune regulation
GO Annotations:  Associated to 6 GO processes
GO:0030449 regulation of complement activation TAS
GO:0050776 regulation of immune response TAS
GO:0050851 antigen receptor-mediated signaling pathway IDA
GO:0050853 B cell receptor signaling pathway IBA
GO:0050855 regulation of B cell receptor signaling pathway IMP
GO:0050864 regulation of B cell activation IDA
Immuno Process:  Cellular signalling
GO Annotations:  Associated to 6 GO processes
GO:0002322 B cell proliferation involved in immune response IDA
GO:0050851 antigen receptor-mediated signaling pathway IDA
GO:0050853 B cell receptor signaling pathway IBA
GO:0050855 regulation of B cell receptor signaling pathway IMP
GO:0050864 regulation of B cell activation IDA
click arrow to show/hide IEA associations
GO:0001923 B-1 B cell differentiation IEA
Immuno Process:  B cell (activation)
GO Annotations:  Associated to 5 GO processes, IEA only
GO:0002322 B cell proliferation involved in immune response IDA
GO:0016064 immunoglobulin mediated immune response IMP
GO:0019724 B cell mediated immunity IMP
GO:0050864 regulation of B cell activation IDA
click arrow to show/hide IEA associations
GO:0001923 B-1 B cell differentiation IEA
Immuno Process:  Immune system development
GO Annotations:  Associated to 1 GO processes, IEA only
click arrow to show/hide IEA associations
GO:0001923 B-1 B cell differentiation IEA
Immuno Process:  T cell (activation)
GO Annotations:  Associated to 2 GO processes
GO:0016064 immunoglobulin mediated immune response IMP
GO:0019724 B cell mediated immunity IMP
Immuno Disease Associations
Disease Name:  Acute lymphocytic leukemia (ALL)
Disease Synonyms:  no synonynms
Comment:  CD19 is one of the molecular targets of the bi-specific antibody drug blinatumomab (also binds CD3e).
Disease X-refs:  OMIM: 613065
References: 
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  Immunodeficiency, common variable, 3; CVID3
Synonyms: Common variable immunodeficiency [Orphanet: ORPHA1572] [Disease Ontology: DOID:12177]
Disease Ontology: DOID:12177
OMIM: 613493
Orphanet: ORPHA1572

References

Show »

1. Damschroder M, Kiener P, Wu H, Dall'Acqua W, Herbst R, Coyle A. (2012) Humanized anti-CD19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease. Patent number: US8323653 B2. Assignee: Medimmune, Llc. Priority date: 08/09/2006. Publication date: 04/12/2012.

2. Dreier T, Lorenczewski G, Brandl C, Hoffmann P, Syring U, Hanakam F, Kufer P, Riethmuller G, Bargou R, Baeuerle PA. (2002) Extremely potent, rapid and costimulation-independent cytotoxic T-cell response against lymphoma cells catalyzed by a single-chain bispecific antibody. Int J Cancer, 100 (6): 690-7. [PMID:12209608]

3. Horton HM, Bernett MJ, Pong E, Peipp M, Karki S, Chu SY, Richards JO, Vostiar I, Joyce PF, Repp R et al.. (2008) Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia. Cancer Res, 68 (19): 8049-57. [PMID:18829563]

4. Tedder TF, Isaacs CM. (1989) Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. J Immunol, 143 (2): 712-7. [PMID:2472450]

How to cite this page

CD molecules: CD19. Last modified on 22/07/2020. Accessed on 13/04/2021. IUPHAR/BPS Guide to PHARMACOLOGY, http://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=2764.